文献速递肝病

直接抗病毒药物时期精神健康或物质使用障碍患者丙型肝炎治疗可及性是否改变

Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
PubMed 文献 · Hepatology · 2018-12-18

该回顾性分析纳入美国四个大型多元医疗系统中29544例慢性丙型肝炎成人,比较直接抗病毒药物(DAA)前(2011年1月1日至2013年12月31日)与后(2014年1月1日至2017年2月28日)治疗获得情况。DAA后治疗率21.7%(2879/13240)高于DAA前3.5%(574/16304);合并精神健康或物质使用障碍(MH/SUD)者在DAA前后均更少接受治疗。

要点

  • DAA后慢性丙型肝炎治疗率21.7%(2879/13240),DAA前为3.5%(574/16304)。
  • 合并MH/SUD者治疗可能性在DAA前(AOR 0.46;95%CI 0.36,0.60)和DAA后(AOR 0.63;95%CI 0.55,0.71)均低于无MH/SUD者。
  • 2011至2017年MH/SUD者累计治疗风险13.6% vs 无MH/SUD者21.6%(P<0.001)。

核心结论

  • DAA后丙型肝炎治疗患者数量增加,尤其是合并肝脏相关合并症者,但合并MH/SUD者在治疗可及性上仍存在差异。

研究设计与样本

  • 回顾性分析美国四个大型多元医疗系统中29544例慢性丙型肝炎成人,比较DAA前(2011年1月1日至2013年12月31日)与DAA后(2014年1月1日至2017年2月28日)的治疗情况。

主要发现

  • DAA后慢性丙型肝炎治疗率为21.7%(2879/13240),DAA前为3.5%(574/16304)。
  • DAA后西班牙裔白人相比非西班牙裔白人治疗可能性更低(AOR 0.36;95%CI 0.25,0.52)。
  • DAA后合并非酒精性脂肪性肝病(AOR 1.39;95%CI 1.05,1.83)、肝硬化(AOR 2.00;95%CI 1.74,2.31)和肝移植(AOR 2.72;95%CI 1.87,3.94)者治疗可能性更高。
  • 合并MH/SUD者在DAA前(AOR 0.46;95%CI 0.36,0.60)和DAA后(AOR 0.63;95%CI 0.55,0.71)治疗可能性均更低。
  • 2011至2017年合并MH/SUD者累计治疗风险13.6% vs 无MH/SUD者21.6%(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Direct-acting antivirals (DAA) for hepatitis C virus (HCV) became available in 2014, but the role of mental health or substance use disorders (MH/SUD) on access to treatment is unknown. The objective of this study was to examine the extent and predictors of HCV treatment in the pre-DAA and post-DAA periods in four large, diverse health care settings in the United States. We conducted a retrospective analysis of 29,544 adults with chronic HCV who did or did not receive treatment from January 1, 2011, to February 28, 2017. Kaplan-Meier curve was used to examine cumulative risk for receiving HCV treatment stratified by MH/SUD. Predictors of HCV treatment in the pre-DAA (January 1, 2011, to December 31, 2013) and post-DAA (January 1, 2014, to February 28, 2017) cohorts were analyzed using multivariate generalized estimating equations and a modified Poisson model. Overall, 21.7% (2,879/13,240) of those with chronic HCV post-DAA were treated compared with 3.5% (574/16,304) in the pre-DAA period. Compared with non-Hispanic whites, Hispanic whites (adjusted odds ratio [AOR] 0.36; 95% confidence interval [CI], 0.25, 0.52) were less likely to be treated in the post-DAA period. Those with concurrent nonalcoholic fatty liver disease (AOR 1.39; 95% CI, 1.05, 1.83), cirrhosis (AOR 2.00; 95% CI, 1.74, 2.31), and liver transplant (AOR 2.72; 95% CI, 1.87, 3.94) were more likely to be treated post-DAA. Those with MH/SUD were less likely to be treated both before (AOR 0.46; 95% CI, 0.36, 0.60) and after (AOR 0.63; 95% CI, 0.55, 0.71) DAA therapy was available. Overall, the cumulative risk for receiving HCV treatment from 2011 to 2017 among those with versus without MH/SUD was 13.6% versus 21.6%, respectively (P < 0.001). Conclusion: The volume of patients treated for HCV has increased in the post-DAA period, especially among those with liver-related comorbidities, but disparities in access to treatment continue among those with MH/SUD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Jain MK, Thamer M, Therapondos G, et al. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period? Hepatology. 2018. PMID: 30019478. doi:10.1002/hep.30171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。